Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings

Journal of Patient-Reported Outcomes

Table 2 Patient interviews: Clinician-reported patient health information^a

	Total (N = 15) n (%)^b
Menopausal status
Pre-menopausal	3 (20.0%)
Not on gonadotropin-releasing hormone (GnRH) agonist treatment	3 (100.0%) ^c
Post-menopausal	12 (80.0%)
Mammalian target of rapamycin (mTOR) inhibitor treatment
Yes	3 (20.0%)
No	12 (80.0%)
Recurrent or progressive disease refractory to non-steroidal aromatase inhibitor (NSAI), tamoxifen, or fulvestrant
Yes	6 (40.0%)
No	9 (60.0%)
Eastern Cooperative Oncology Group score
0	1 (6.7%)
1	11 (73.3%)
2	3 (20.0%)
Cyclin-dependent kinase (CDK4/6) inhibitor treatment
Yes	5 (33.3%)
No	10 (66.7%)
Metastatic site^d
Bone	13 (86.7%)
Lung	2 (13.3%)
Liver	3 (20.0%)
Lymph node	1 (6.7%)
Skin	1 (6.7%)

^aInformation reported by clinician on the Subject Clinical Screener
^bUnless other statistic indicated
^cThis characteristic was only reported by the clinician for subjects who were pre-menopausal at diagnosis. The clinician for one subject reported menopausal status at the time of the study (post-menopausal); however, it was determined that treatment caused the subject to begin menopause. Thus, the subject is characterized as pre-menopausal. Data for this subject regarding treatment with a GnRH agonist were not provided
^dResponses are not mutually exclusive